Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia
Clinical trial NCT00976248 · COMPLETED
Trial details
- NCT number
- NCT00976248
- Sponsor
- Dana-Farber Cancer Institute
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2009-11-01
- Primary completion
- 2016-07-01
- Enrollment
- 33
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.